Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

MicroRNAs01:22

MicroRNAs

3.8K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.8K
MicroRNAs01:22

MicroRNAs

23.9K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiovascular disease and miRNA.

Advances in clinical chemistry·2026
Same author

Limited Nrf2 activation and heterogeneous thyroidal effects in a 424-compound multi-assay screen call for rigorous testing of purported antioxidant and health-promoting supplements.

Redox biology·2026
Same author

Metformin as a potential therapeutic agent in broken heart syndrome: Targeting AMPK-dependent cardio-protection and microvascular function.

Molecular biology reports·2026
Same author

Deciphering the Chemotherapeutic Mechanism of Ferulic Acid: Insight Into the Role Against Multiple Human Cancers.

Cancer innovation·2026
Same author

MiR-126 prevents hypoxic HUVEC cellular injury through targeting TRAF6 expression.

Cardiovascular journal of Africa·2026
Same author

Mapping the intersection of social status and comorbidity in knee osteoarthritis: A WOMAC-based study.

PloS one·2026
Same journal

Correction: Verde et al. Molecular Mechanisms of Protein Aggregation in ALS-FTD: Focus on TDP-43 and Cellular Protective Responses. <i>Cells</i> 2025, <i>14</i>, 680.

Cells·2026
Same journal

Inflammation in Cardiomyopathies: Cellular Mechanisms Across Cardiac Phenotype.

Cells·2026
Same journal

IL-4/IL-13-Driven Dysregulation of Epidermal Lipid Metabolism in Atopic Dermatitis: An Immunometabolic Link Between Type 2 Inflammation and Barrier Dysfunction.

Cells·2026
Same journal

Activity of DNA- and RNA-Guided Prokaryotic Argonautes in Human Mitochondria.

Cells·2026
Same journal

Placental Pathophysiology in Maternal Psychoactive Substance Use: Biological, Clinical, and Forensic Perspectives.

Cells·2026
Same journal

PACAP and Maxadilan (PAC1 Agonist) Influence Plaque Progression, Migratory Ability, and Mitochondrial Morphology and Dynamics in Vascular Smooth Muscle Cells.

Cells·2026
See all related articles

Related Experiment Video

Updated: Jan 15, 2026

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

7.9K

MicroRNA-21 Protects Hypoxic-Induced Cardiomyocytes Injury by Targeting Smad-7.

Md Sayed Ali Sheikh1, A Alduraywish1, Basil Mohammed Alomair1

  • 1Internal Medicine Department, College of Medicine, Jouf University, Sakaka 72345, Saudi Arabia.

Cells
|October 15, 2025
PubMed
Summary
This summary is machine-generated.

MicroRNAs miR-21, miR-488, and miR-126 show diagnostic potential for acute myocardial infarction (AMI). Inhibiting miR-21 may offer a therapeutic target for AMI by reducing cellular injury.

Keywords:
H9c2 cellsSmad-7acute myocardial infarctionagingbiomarkersmicroRNAs

More Related Videos

In vitro Assessment of Myocardial Protection following Hypothermia-Preconditioning in a Human Cardiac Myocytes Model
08:22

In vitro Assessment of Myocardial Protection following Hypothermia-Preconditioning in a Human Cardiac Myocytes Model

Published on: October 27, 2020

3.4K
Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization
08:22

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization

Published on: September 15, 2018

8.6K

Related Experiment Videos

Last Updated: Jan 15, 2026

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

7.9K
In vitro Assessment of Myocardial Protection following Hypothermia-Preconditioning in a Human Cardiac Myocytes Model
08:22

In vitro Assessment of Myocardial Protection following Hypothermia-Preconditioning in a Human Cardiac Myocytes Model

Published on: October 27, 2020

3.4K
Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization
08:22

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization

Published on: September 15, 2018

8.6K

Area of Science:

  • Cardiovascular Research
  • Molecular Biology
  • Biomarker Discovery

Background:

  • Acute myocardial infarction (AMI) is a leading cause of sudden cardiac death globally.
  • Understanding the molecular mechanisms and diagnostic markers of AMI is crucial for improving patient outcomes.

Purpose of the Study:

  • To investigate the diagnostic role of plasma miR-21, miR-488, and miR-126 in patients with acute myocardial infarction (AMI).
  • To explore the molecular impact of miR-21 inhibition on hypoxia-induced cellular injury in H9c2 cells.
  • To assess the potential of these microRNAs as clinical biomarkers for AMI.

Main Methods:

  • Analysis of plasma microRNA levels in 95 non-ST-elevation myocardial infarction (NSTEMI) patients, 152 ST-elevation myocardial infarction (STEMI) patients, and 95 healthy controls.
  • Utilized three-month-old mice and ventricular-derived H9c2 cells for cellular studies.
  • Employed receiver operating characteristic (ROC) curve analysis for diagnostic assessment and in vitro experiments with miR-21 inhibitors on H9c2 cells.

Main Results:

  • Plasma miR-21 and miR-488 levels were significantly upregulated, while miR-126 levels were downregulated in NSTEMI and STEMI patients compared to healthy individuals.
  • ROC curve analysis confirmed the diagnostic capability of these microRNAs in differentiating AMI patients from controls.
  • Inhibition of miR-21 in H9c2 cells reduced reactive oxygen species (ROS), caspase-3 activity, and apoptosis, while enhancing viability by upregulating Smad-7 expression.

Conclusions:

  • Circulating miR-21, miR-488, and miR-126 are potential biomarkers for diagnosing AMI.
  • Inhibition of miR-21 presents a promising therapeutic strategy for AMI by mitigating hypoxia-induced cellular damage through Smad-7 targeting.
  • Elevated plasma miR-21 levels in geriatric AMI patients warrant further investigation, and low miR-21 may impact aging processes.